InvestSMART

Optiscan Imaging Limited (ASX:OIL)

ALERT: Price-sensitive ASX Announcement for OIL
Current share price for OIL : $0.165 0.025 (17.86%)+
Announcement
Release
22 Jul 2026 8:25AM
Price at Release
$0.140
Full Release
download
Summary
Optiscan Imaging Ltd has initiated a US clinical study in partnership with Mayo Clinic to evaluate its InVue™ and InForm™ imaging devices in breast cancer surgeries. The study will involve 35 patients and aims to validate the devices for potential FDA 510(k) submissions, supporting AI development in cancer tissue assessment. This initiative is strategically significant for enhancing Optiscan's surgical-pathology workflow integration and commercial expansion into the US market.
Key Points
  • Optiscan Imaging Ltd has signed a new Research Agreement with Mayo Clinic for a US breast cancer imaging study.
  • The study will evaluate Optiscan's InVue™ for in vivo surgical imaging and InForm™ for ex vivo digital pathology imaging.
  • 35 US patients undergoing breast-conserving surgery will be recruited for the study.
  • The study aims to generate clinical evidence for FDA 510(k) submissions and support the development of AI for breast cancer tissue assessment.
  • InVue™ and InForm™ devices will be assessed for their utility in surgical-pathology workflow integration.
  • The collaboration aims to advance precision-guided breast cancer surgery and enhance clinical expansion.
  • The study could support Optiscan’s strategy of building a connected digital ecosystem for cancer surgery and pathology assessment.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.